Nerdwallet Inc vs Novo Nordisk A/S — how do they compare? Nerdwallet Inc trades at $9.5 (market cap $625.17M), while Novo Nordisk A/S trades at $46.15 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 332.5× Nerdwallet Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | NVO | |
|---|---|---|
Market Cap | $625.17M | $207.85B |
Sector | Financials | Health |
52-Week High | $15.93 | $63.98 |
52-Week Low | $7.58 | $35.29 |
Enterprise Value | $539.47M | $222.55B |
Dividend Yield | — | 3.81% |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.48, down 3.27% today, amid mixed signals. The stock shows bullish technical momentum with a 10.87 P/E ratio indicating potential undervaluation. Revenue grew to $836.6M in 2025, with net income reaching $48.7M, though Q2 2026 earnings missed expectations. Positive analyst sentiment includes a 66.66% buy rating, with news highlighting a 27.9% upside potential from Zacks Investment Research on August 10, 2026.
Outlook is cautiously optimistic with strong profitability margins and cash flow growth, but risks include organic-search pressure and competitive threats. The stock's valuation and recent momentum suggest upside, though investors must monitor earnings consistency and market volatility.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Trailing returns across standard periods
Latest headlines on both assets
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →